Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02411773 · ClinicalTrials.gov registry record · Phase 1

Sympatholysis in Chronic Kidney Disease

A Phase 1 study of Chronic Kidney Disease, sponsored by Emory University.

Recruiting
Registry status
Phase 1
Development phase
110
Enrollment target
1
Study location

NCT02411773: Recruiting Phase 1 study of Chronic Kidney Disease, sponsored by Emory University.

NCT02411773 is a Phase 1 study of Chronic Kidney Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 110 participants, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02411773, a Phase 1 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 1
Development phase
110 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

Primary Outcome

Near-infrared spectroscopy (NIRS) will measure and record tissue oxyhemoglobin, deoxyhemoglobin, and total hemoglobin.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Sodium Bicarbonate
  • BEHAVIORAL Exercise Training
  • BEHAVIORAL Control to Exercise (Stretching)

Study Locations (1)

Georgia

  • Atlanta VA Medical Center - Decatur

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2015-06-11
Est. Completion 2027-06
Phase Phase 1
Emory University

1,208 total trials

What NCT02411773 shows while recruiting

NCT02411773 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 3,206-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02411773 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02411773 about?

NCT02411773 is a clinical study titled "Sympatholysis in Chronic Kidney Disease". The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate).

What is the current status of trial NCT02411773?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2015-06-11. Estimated completion is 2027-06.

What conditions does trial NCT02411773 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT02411773?

The interventions under investigation include: Placebo (DRUG), Sodium Bicarbonate (DRUG), Exercise Training (BEHAVIORAL), Control to Exercise (Stretching) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02411773?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02411773 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02411773's enrollment target sits among peer trials

110 55th of 101 higher than 47 of 101 other Chronic Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01530373 · 110 participants · Phase 2

    Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients

  • NCT02379377 · 110 participants · Phase 1

    18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

  • NCT03190941 · 110 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

  • NCT03245411 · 110 participants · NA

    Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02411773, the US trial registry maintained by the National Library of Medicine. NCT02411773 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.